The Study of Cost-Effectiveness of Rivaroxaban versus Warfarin in Patients with Atrial Fibrillation Who Developed Ischemic Stroke

The Study of Cost-Effectiveness of Rivaroxaban versus Warfarin in Patients with Atrial Fibrillation Who Developed Ischemic Stroke

Introduction. Rivaroxaban is a new anticoagulant providing benefits for the treatment of patients with atrial fibrillation (AF). This study is aimed at evaluating the cost-effectiveness of rivaroxaban compared to warfarin in patients with AF. Method. This economic evaluation study was conducted amon...

Full description

Bibliographic Details
Main Authors: Neda Jaberi, Zahra Kavosi, Etrat Hooshmandi, Nasrin Moradi, Khosro Keshavarz, Afshin Borhani-Haghighi
Format: Article
Language:English
Published: Hindawi Limited 2021-01-01
Series:Stroke Research and Treatment
Online Access:http://dx.doi.org/10.1155/2021/5534873

Similar Items

Similar Items